Clinical Trial Update: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study evaluating adding 131I-MIBG or lorlatinib to intensive therapy for high-risk neuroblastoma; the trial is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ganglioneuroblastoma
• Neuroblastoma

Drugs mentioned

• 131I-MIBG (metaiodobenzylguanidine)
• Lorbrena (lorlatinib)

Snippet

Sponsor: Children's Oncology Group | Conditions: Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular | Phase 3 | Status: RECRUITING